AUTHORS
Karin Dembrower, MD
Alessio Crippa, PhD
Eugenia Colón, MD
Prof Martin Eklund, PhD
Fredrik Strand, MD
and theScreenTrustCAD Trial Consortium
Trial Consortium Members
Karin Dembrower, Capio S:t Göran Hospital and Karolinska Institutet
Alessio Crippa, Karolinska Institutet
Eugenia Colón, Capio S:t Göran Hospital
Martin Eklund, Karolinska Institutet
Fredrik Strand, Karolinska University Hospital and Karolinska Institutet
Anders Byström, Capio S:t Göran Hospital
Jonathan Waldenström, Capio S:t Göran Hospital
Lennart Skärblom, Capio S:t Göran Hospital
Astrid Rocchi, Capio S:t Göran Hospital
Kjell Hågemo, Capio S:t Göran Hospital Karin Torneman, Capio S:t Göran Hospital
Ingrid Wiklander-Bråkenhielm, Capio S:t Göran Hospital
Johanna Swärd, Capio S:t Göran Hospital
Maria Balarova, Capio S:t Göran Hospital
Anca Plotoaga, Capio S:t Göran Hospital
Edith Herterich Capio S:t göran Hospital
PUBLISHED
Summary
Background
Artificial intelligence (AI) as an independent reader of screening mammograms has shown promise, but there are few prospective studies. Our aim was to conduct a prospective clinical trial to examine how AI affects cancer detection and false positive findings in a real-world setting.
Methods
ScreenTrustCAD was a prospective, population-based, paired-reader, non-inferiority study done at the Capio Sankt Göran Hospital in Stockholm, Sweden. Consecutive women without breast implants aged 40–74 years participating in population-based screening in the geographical uptake area of the study hospital were included. The primary outcome was screen-detected breast cancer within 3 months of mammography, and the primary analysis was to assess non-inferiority (non-inferiority margin of 0·15 relative reduction in breast cancer diagnoses) of double reading by one radiologist plus AI compared with standard-of-care double reading by two radiologists. We also assessed single reading by AI alone and triple reading by two radiologists plus AI compared with standard-of-care double reading by two radiologists. This study is registered with ClinicalTrials.gov, NCT04778670.
Findings
From April 1, 2021, to June 9, 2022, 58 344 women aged 40–74 years underwent regular mammography screening, of whom 55 581 were included in the study. 269 (0·5%) women were diagnosed with screen-detected breast cancer based on an initial positive read: double reading by one radiologist plus AI was non-inferior for cancer detection compared with double reading by two radiologists (261 [0·5%] vs 250 [0·4%] detected cases; relative proportion 1·04 [95% CI 1·00–1·09]). Single reading by AI (246 [0·4%] vs 250 [0·4%] detected cases; relative proportion 0·98 [0·93–1·04]) and triple reading by two radiologists plus AI (269 [0·5%] vs 250 [0·4%] detected cases; relative proportion 1·08 [1·04–1·11]) were also non-inferior to double reading by two radiologists.
Interpretation
Replacing one radiologist with AI for independent reading of screening mammograms resulted in a 4% higher non-inferior cancer detection rate compared with radiologist double reading. Our study suggests that AI in the study setting has potential for controlled implementation, which would include risk management and real-world follow-up of performance.
Funding
Swedish Research Council, Swedish Cancer Society, Region Stockholm, and Lunit.